Department of Neurology, Barzilai Medical Center, 2 Hahistadrut St., Ashkelon 78278, Israel.
J Neuroimmunol. 2011 Feb;231(1-2):23-31. doi: 10.1016/j.jneuroim.2010.10.021. Epub 2010 Dec 15.
The multifaceted pathogenesis of multiple sclerosis (MS) involves complex interactions between the immune and the central nervous systems which provide a multitude of targets for therapeutic interventions. Current therapies for MS are only partially effective. One potential strategy to increase treatment efficacy is the combination of two or more drugs with complementary mechanisms of action, which may result in additive or synergistic therapeutic effects. In this review, we discuss the rationale and requirements and review the evidence for combination therapy in MS from in-vitro experiments, animal studies and clinical trials. Encouraging experience to date and further well-designed clinical trials with combination therapy may lead to the implementation of specific combinations of drugs in the treatment of MS.
多发性硬化症（MS）的多因素发病机制涉及免疫系统和中枢神经系统之间的复杂相互作用，为治疗干预提供了众多靶点。目前 MS 的治疗方法仅部分有效。增加治疗效果的一种潜在策略是将两种或多种具有互补作用机制的药物联合使用，这可能会产生相加或协同的治疗效果。在这篇综述中，我们讨论了联合治疗的原理、要求，并从体外实验、动物研究和临床试验等方面回顾了 MS 联合治疗的证据。迄今为止令人鼓舞的经验和进一步设计良好的联合治疗临床试验可能会导致在 MS 治疗中实施特定药物的联合。
